Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APVO NASDAQ:CNSP NASDAQ:INM NASDAQ:ZVSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$1.52-0.7%$1.64$1.32▼$298.00$5M5.874.64 million shs685,567 shsCNSPCNS Pharmaceuticals$8.25+2.5%$7.98$4.93▼$114.00$4.74M2.6825,273 shs9,101 shsINMInMed Pharmaceuticals$2.07+2.0%$2.21$1.72▼$8.27$4.94M0.3116,064 shs50,543 shsZVSAZyVersa Therapeutics$0.16+10.9%$0.15$0.11▼$3.37$1.27M0.832.64 million shs12,152 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics0.00%-3.80%-5.00%-50.33%-99.98%CNSPCNS Pharmaceuticals0.00%-10.33%-4.62%-6.46%-90.25%INMInMed Pharmaceuticals0.00%-1.43%-5.05%-21.59%-65.15%ZVSAZyVersa Therapeutics0.00%+14.38%-10.42%-40.78%-92.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$1.52-0.7%$1.64$1.32▼$298.00$5M5.874.64 million shs685,567 shsCNSPCNS Pharmaceuticals$8.25+2.5%$7.98$4.93▼$114.00$4.74M2.6825,273 shs9,101 shsINMInMed Pharmaceuticals$2.07+2.0%$2.21$1.72▼$8.27$4.94M0.3116,064 shs50,543 shsZVSAZyVersa Therapeutics$0.16+10.9%$0.15$0.11▼$3.37$1.27M0.832.64 million shs12,152 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics0.00%-3.80%-5.00%-50.33%-99.98%CNSPCNS Pharmaceuticals0.00%-10.33%-4.62%-6.46%-90.25%INMInMed Pharmaceuticals0.00%-1.43%-5.05%-21.59%-65.15%ZVSAZyVersa Therapeutics0.00%+14.38%-10.42%-40.78%-92.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPVOAptevo Therapeutics 2.33HoldN/AN/ACNSPCNS Pharmaceuticals 2.33Hold$20.00142.42% UpsideINMInMed Pharmaceuticals 1.00SellN/AN/AZVSAZyVersa Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ZVSA, APVO, INM, and CNSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025INMInMed PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/24/2025CNSPCNS PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025APVOAptevo TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E)10/8/2025CNSPCNS PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025INMInMed PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025APVOAptevo TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E)9/27/2025CNSPCNS PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025INMInMed PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/18/2025APVOAptevo TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/16/2025APVOAptevo TherapeuticsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/12/2025CNSPCNS PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$20.00(Data available from 10/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPVOAptevo Therapeutics$3.11M1.61N/AN/A$65.21 per share0.02CNSPCNS PharmaceuticalsN/AN/AN/AN/A$64.50 per shareN/AINMInMed Pharmaceuticals$4.94M1.00N/AN/A$6.71 per share0.31ZVSAZyVersa TherapeuticsN/AN/AN/AN/A$3.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPVOAptevo Therapeutics-$24.13M-$444.03N/AN/AN/AN/A-675.52%-175.68%11/6/2025 (Estimated)CNSPCNS Pharmaceuticals-$14.86M-$175.45N/A∞N/AN/A-183.89%-139.37%11/13/2025 (Estimated)INMInMed Pharmaceuticals-$8.16M-$12.09N/A∞N/A-165.12%-93.19%-74.49%11/13/2025 (Estimated)ZVSAZyVersa Therapeutics-$9.41MN/A0.00N/AN/AN/A-109.54%-43.95%11/13/2025 (Estimated)Latest ZVSA, APVO, INM, and CNSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025N/AAPVOAptevo Therapeutics-$2.09N/AN/AN/AN/AN/A8/14/2025Q2 2025CNSPCNS Pharmaceuticals-$9.60-$6.42+$3.18-$6.42N/AN/A8/11/2025Q2 2025APVOAptevo Therapeutics-$83.20-$8.40+$74.80-$8.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPVOAptevo TherapeuticsN/AN/AN/AN/AN/ACNSPCNS PharmaceuticalsN/AN/AN/AN/AN/AINMInMed PharmaceuticalsN/AN/AN/AN/AN/AZVSAZyVersa TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPVOAptevo TherapeuticsN/A2.272.27CNSPCNS PharmaceuticalsN/A10.2210.22INMInMed Pharmaceuticals0.026.996.47ZVSAZyVersa TherapeuticsN/A0.180.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPVOAptevo Therapeutics8.06%CNSPCNS Pharmaceuticals14.02%INMInMed Pharmaceuticals20.12%ZVSAZyVersa Therapeutics3.91%Insider OwnershipCompanyInsider OwnershipAPVOAptevo Therapeutics0.01%CNSPCNS Pharmaceuticals0.07%INMInMed Pharmaceuticals1.43%ZVSAZyVersa Therapeutics0.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPVOAptevo Therapeutics503.29 million3.29 millionNot OptionableCNSPCNS Pharmaceuticals5570,000575,000Not OptionableINMInMed Pharmaceuticals102.38 million2.35 millionNot OptionableZVSAZyVersa Therapeutics27.94 million4.86 millionNot OptionableZVSA, APVO, INM, and CNSP HeadlinesRecent News About These CompaniesZyVersa Therapeutics Faces Nasdaq Delisting NoticeSeptember 18, 2025 | tipranks.comZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term ...September 10, 2025 | markets.businessinsider.comZyVersa Therapeutics Highlights Role of Inflammasomes in Type 2 Diabetes and Cardiovascular Complications with Promising Data on IC 100September 10, 2025 | quiverquant.comQZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular OutcomesSeptember 10, 2025 | globenewswire.comZyVersa Therapeutics highlights lipidomic data in Alport Syndrome, DKDSeptember 3, 2025 | msn.comZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease ...September 3, 2025 | finance.yahoo.comZyVersa Therapeutics Initiates Phase 2a Clinical Trial for Cholesterol Efflux Mediator™ VAR 200 in Diabetic Kidney Disease PatientsSeptember 3, 2025 | quiverquant.comQZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease ProgressionSeptember 3, 2025 | globenewswire.comZyVersa Therapeutics Reports Financial Challenges Amid Nasdaq DelistingAugust 20, 2025 | msn.comZyVersa Therapeutics reports Q2 EPS (46c) vs. ($3.31) last yearAugust 14, 2025 | msn.comZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address ...August 14, 2025 | bakersfield.comBZyVersa Therapeutics highlights data on role of lipotoxicity in DKDAugust 14, 2025 | msn.comZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its ProgressionAugust 14, 2025 | globenewswire.comZyVersa Therapeutics Activates First Clinical Site for Phase 2a Trial of VAR 200 in Diabetic Kidney Disease and Reports Progress in Product DevelopmentAugust 13, 2025 | quiverquant.comQZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building MilestonesAugust 13, 2025 | globenewswire.comZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D ProgressJuly 21, 2025 | globenewswire.comZyVersa Touches 52-Week Low; Nasdaq to Suspend Trading ThursdayJuly 16, 2025 | marketwatch.comZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds | MorningstarJuly 9, 2025 | morningstar.comMZyVersa’s VAR 200 approved for emergency use in rare kidney diseaseJuly 9, 2025 | uk.investing.comZyVersa Therapeutics Supports Emergency Compassionate Use of VAR 200 for Patient with ApoCII Amyloidosis - NasdaqJuly 9, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Datavault AI: The New AI Contender Backed by Big FundingBy Jeffrey Neal Johnson | October 1, 2025Robinhood Up 12%—Could Prediction Markets Be Its Secret Weapon?By Leo Miller | October 3, 20253 Travel Stocks to Watch Heading Into the HolidaysBy Chris Markoch | October 6, 2025ZVSA, APVO, INM, and CNSP Company DescriptionsAptevo Therapeutics NASDAQ:APVO$1.52 -0.01 (-0.65%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$1.52 +0.00 (+0.33%) As of 10/24/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.CNS Pharmaceuticals NASDAQ:CNSP$8.25 +0.20 (+2.48%) Closing price 10/24/2025 03:51 PM EasternExtended Trading$8.29 +0.04 (+0.48%) As of 10/24/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.InMed Pharmaceuticals NASDAQ:INM$2.07 +0.04 (+1.97%) Closing price 10/24/2025 03:59 PM EasternExtended Trading$2.08 +0.02 (+0.72%) As of 10/24/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.ZyVersa Therapeutics NASDAQ:ZVSA$0.16 +0.02 (+10.89%) As of 10/24/2025 03:56 PM EasternZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
